Core Insights - The Pharmacy & Consumer Wellness segment at CVS Health is experiencing strong growth, with a revenue increase of 11.8% in the first half of 2025, driven by a favorable pharmacy drug mix and higher prescription volumes [1][8] - CVS has successfully executed its operational strategies across its 9,000 community health locations, supported by a workforce of over 200,000, despite facing pharmacy reimbursement pressures [1] - The front store business is improving due to an expanding customer base and retail share gains, bolstered by the acquisition of Rite Aid assets and prescription files from 626 pharmacies [2][8] - The CVS CostVantage pharmacy reimbursement model is stabilizing margins and enhancing transparency for payors, addressing industry challenges [3][8] - The Zacks Consensus Estimate predicts a 7.4% year-over-year revenue improvement for CVS' Pharmacy & Consumer Wellness segment in the third quarter [4] Financial Performance - CVS Health shares have increased by 46.5% over the past year, significantly outperforming the industry, which saw a decline of 3.1% [7] - The forward five-year price/sales ratio for CVS is 0.25X, compared to the industry's 0.48X, indicating a discount [9] - The Zacks Consensus Estimate for CVS Health's 2025 EPS has risen by 3.9% in the last 90 days, although trends for 2026 are mixed [10] Market Context - Walmart is set to report its fiscal 2026 third-quarter earnings soon and has announced significant discounts for its upcoming Black Friday and Cyber Monday events [5] - Amazon is preparing to release its third-quarter results and has launched a new private-label grocery brand, expanding its market presence [6]

Core Insights - The article emphasizes the importance of understanding macro trends and their influence on asset prices and investor behavior, particularly in the context of equity analysis and research [1]. Group 1: Professional Background - The author has over 10 years of experience in asset management, focusing on equity analysis, macroeconomics, and risk-managed portfolio construction [1]. - The professional background includes advising on and implementing multi-asset strategies, with a strong emphasis on equities and derivatives [1]. Group 2: Investment Philosophy - The article advocates for making investing accessible, inspiring, and empowering, highlighting the value of sharing insights and building confidence in long-term investing [1]. - The author encourages readers to conduct their own research before making investment decisions, reinforcing the idea that past performance does not guarantee future results [2].

Core Insights - The article emphasizes the importance of understanding macro trends and their influence on asset prices and investor behavior, particularly in the context of equity analysis and research [1]. Group 1: Professional Background - The author has over 10 years of experience in asset management, focusing on equity analysis, macroeconomics, and risk-managed portfolio construction [1]. - The professional background includes advising on and implementing multi-asset strategies, with a strong emphasis on equities and derivatives [1]. Group 2: Investment Philosophy - The goal of sharing insights is to make investing accessible, inspiring, and empowering for fellow investors [1]. - The author encourages building confidence in long-term investing through shared knowledge and collaboration [1].

Don’t miss your chance to be part of the Forbes Healthcare Summit in NYC on 12/4. Join healthcare industry leaders and speakers from Humana, CVS Health, Epic and other top companies. With limited spots and high demand, now’s the time to apply to attend. Check out the incredible speaker lineup today! https://t.co/1ay9z4AxlP ...

Core Viewpoint - Charlie Bilello criticizes government inflation data, particularly the calculation of health insurance costs, claiming it is misleading and inaccurate [1][4]. Health Insurance Costs - Government data suggests health insurance prices have decreased by 18% over the last five years, while Bilello argues they have actually increased by 26% during the same period [2][3]. - The average family health insurance premium has reached nearly $27,000 per year, marking a 365% increase from just under $6,000 in 1999 [3]. Government Methodology - Bilello describes the government's methodology as flawed, stating it relies on insurer profits rather than actual premiums paid by consumers [2][3]. - He emphasizes that the focus should be on the actual costs of health insurance rather than retained earnings of health insurance companies [3]. Impact on Public Trust - The inaccuracies in government data contribute to a misleading perception of overall inflation and undermine public trust in government statistics [4]. Health Insurer Performance - A summary of publicly traded health insurers shows varied year-to-date and one-year performance, with UnitedHealth Group Inc. experiencing a significant decline of 28.15% YTD [5]. - CVS Health Corp. stands out with an 85.28% YTD performance, while Centene Corp. has the lowest performance at -43.70% YTD [5].

Core Insights - CVS Health is closing 16 Oak Street Health Centers, representing 7% of its senior-focused primary care locations in the U.S. [2] - The closures are attributed to elevated medical costs and reflect a broader trend in the healthcare industry, with other companies like Walgreens and Walmart also reducing their primary care operations [3][4] Company Strategy - Despite the closures, CVS remains committed to the Oak Street model, which aims to improve health outcomes for older adults while managing costs [5] - CVS continues to invest in Oak Street Health, emphasizing the importance of value-based care in the healthcare sector [6] Growth and Operations - Since CVS's acquisition of Oak Street Health two years ago, the company has expanded its operations, with plans for more than 300 centers, each potentially contributing $7 million in adjusted EBITDA by 2026 [7] - Under the new CEO David Joyner, CVS has slowed the opening of new Oak Street centers, maintaining 230 centers across 27 states after the closures [8] - The focus is shifting towards growth in existing centers and investment in technology rather than opening new locations [9]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1]. Group 1: Industry Overview - The performance of the five largest health insurers in the U.S. by market capitalization is discussed, specifically mentioning UnitedHealth Group Incorporated and CVS Health [1]. - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts for investment decisions and buy/sell ratings [1]. Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over five years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the Haggerston BioHealth investing group [1].

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1]. Group 1: Industry Overview - The performance of the five largest health insurers in the U.S. by market capitalization is discussed, specifically mentioning UnitedHealth Group Incorporated and CVS Health [1]. - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts for investment decisions and buy/sell ratings [1]. Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over five years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the Haggerston BioHealth investing group [1].

Group 1 - CVS Health has returned $31 billion to shareholders over the past ten years through dividends and buybacks, achieving an 81% year-to-date return in 2025 after a 42% decline in 2024, indicating a strong recovery in the healthcare sector [2][6] - The company maintains a steady quarterly dividend of $0.665 per share, resulting in an annual dividend of $2.66, which yields approximately 3.64% [3] - In 2024, CVS repurchased approximately 40 million shares and distributed $3.3 billion in dividends, reflecting a disciplined capital allocation strategy [4] Group 2 - CVS stock ranks as the 90th highest total return to shareholders in history, highlighting the effectiveness of its shareholder return strategy [6] - The total capital returned to shareholders as a percentage of market capitalization is inversely related to growth possibilities for reinvestments, with CVS demonstrating a balance between returns and growth potential [9] - CVS has experienced significant declines in the past, including over 62% during the Dot-Com Bubble and around 45% during the Global Financial Crisis, emphasizing the importance of strong fundamentals [10] Group 3 - CVS reported a revenue growth of 5.0% for the last twelve months and an 8.1% average over the last three years, with a free cash flow margin of nearly 1.6% and an operating margin of 2.9% [13] - The stock trades at a P/E multiple of 19.4, offering a lower valuation compared to the S&P while providing higher three-year average revenue growth [13]

Core Insights - Analysts project CVS Health (CVS) will report quarterly earnings of $1.36 per share, a 24.8% increase year over year, with revenues expected to reach $98.29 billion, reflecting a 3% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised upward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Revenue from the Pharmacy & Consumer Wellness Segment is estimated at $35.43 billion, a 9.3% increase year over year [5] - Revenue from Health Care Benefits is projected to reach $34.82 billion, reflecting a 5.5% increase from the previous year [5] - Net revenue from the Health Services segment is expected to be $45.64 billion, indicating a 3.4% year-over-year change [5] Additional Revenue Metrics - Revenue from the Pharmacy & Consumer Wellness Segment - Other is estimated at $597.43 million, a 6.5% increase year over year [6] - The Medical Benefit Ratio (MBR) is projected at 92.3%, down from 95.2% in the same quarter last year [6] Medical Membership Estimates - Total Medical Membership is expected to be 26.58 million, down from 27.15 million year over year [7] - Medical membership for Insured - Medicare Supplement is forecasted at $1.23 billion, compared to $1.29 billion last year [7] Claims and Membership Projections - Pharmacy claims processed are projected to reach 481.18 million, slightly down from 484.10 million year over year [8] - Total Medical Membership for Commercial is expected to be 18.75 million, down from 18.91 million last year [8] - Medicare Advantage - Total membership is estimated at 4.22 million, compared to 4.44 million last year [8] Medicaid and Commercial Membership - Medical membership for Medicaid - Total is projected at $2.39 billion, down from $2.51 billion year over year [9] - Insured - Commercial membership is expected to reach 3.56 million, down from 4.75 million last year [9] Stock Performance - Over the past month, CVS Health shares have returned +8.7%, outperforming the Zacks S&P 500 composite's +1.3% change [9]